ImmunoCult™-ACF树突状细胞分化添加物

用于将人单核细胞分化为树突状细胞的添加物

只有 %1 左

率先评论此产品

¥4,992.00

产品号 #（选择产品）

产品号 #10988_C

用于将人单核细胞分化为树突状细胞的添加物

立即询价

总览

使用无动物成分（ACF）的ImmunoCult™-ACF树突状细胞分化添加物，可从人单核细胞生成未成熟树突状细胞（DC）。

该产品作为ImmunoCult™树突状细胞培养试剂盒的组分，也可单独购买，以方便您的使用。将ImmunoCult™-ACF树突状细胞分化添加物与ImmunoCult™-ACF树突状细胞培养基搭配使用，可在体外生成未成熟DC；当与ImmunoCult™树突状细胞成熟添加物搭配使用时，可支持未成熟DC转化为成熟DC。

关于使用ImmunoCult™树突状细胞培养基进行培养和分化的详细方法，请参阅产品说明书（PIS）。

实验数据

Figure 1. Protocol Diagram.

Mature DCs were generated by culturing EasySep™ isolated monocytes at 1 x 10⁶ cells/mL in ImmunoCult™-ACF Dendritic Cell Medium (Catalog #10987) with added ImmunoCult™-ACF Dendritic Cell Differentiation Supplement (Catalog #10988). At day 3, the medium with differentiation supplement was replaced and cells were incubated for 2 more days. At day 5, without changing the medium, ImmunoCult™ Dendritic Cell Maturation Supplement (Catalog #10989) was added to the culture. At day 7, fully mature DCs were harvested for downstream applications.

Figure 2. Mature DCs generated with ImmunoCult™-ACF Dendritic Cell Medium with Supplements show desired phenotype.

EasySep™ isolated monocytes were cultured and differentiated into mature DCs as described in Figure 1. (A) The percentage of CD14 and CD83 expression in cells at day 7 (mature DCs) was determined by flow cytometry. At day 7, a total of 93 ± 5% of the cells expressed the mature DC marker CD83 and only 1 ± 1% of cells still expressed the monocyte marker CD14 (mean ± SD, n=39). Yield of mature DCs was determined by count of total viable cells at day 7 relative to the count of viable monocytes used for initial culture at day 0. At day 7, the yield of viable mature DCs corresponded to 45 ± 25% (mean ± SD, n=39). (B) Immature DCs were cultured as described in Figure 1. At day 5, cells were cultured with maturation supplement for 2 days (mature DCs) or without maturation supplement (immature DCs). Supernatant was collected at day 7 and IL-12p70 levels were determined by ELISA. Concentrations of IL-12p70 in supernatant of mature and immature DCs were 361 ± 81 and 5 ± 2 pg/mL, respectively (mean ± SEM, n=27).

Figure 3. Mature DCs generated with ImmunoCult™-ACF Dendritic Cell Medium and Supplements induce T cell proliferation.

Mature DCs generated with ImmunoCult™-ACF Dendritic Cell Medium and Supplements (ImmunoCult) or other serum-free competitor media (competitor 1 and 2) and corresponding supplements when applicable (competitor 2), were cultured in ImmunoCult™-XF T Cell Expansion Medium with 1 x 10⁵ CFSE labeled (A) allogeneic CD3+ T cells (MLR assay) or (B) autologous CD8+ T cells (antigen-specific T cell response). (A) Cells were cultured at a DC:T cell ratio of 1:25. (B) Prior to culture with T cells, immature DCs were loaded with HLA Class I peptides derived from the human Cytomegalovirus, Epstein-Barr Virus and Influenza Virus (CEF peptide pool) and stimulated with maturation supplement for 2 days. Cells were cultured at a DC:T cell ratio of 1:4 or 1:10. (A,B) CFSE labeled T cells were incubated in media alone (negative control) or with ImmunoCult™ Human CD3/CD28 T Cell Activator (positive control). After 5-7 days in culture the number of dividing T cells ( CD3⁺CFSE^lo) was assessed by flow cytometry (mean ± SEM) (A) n=5 (B) n=4 (competitor 1 and 2, n=3). Mature DCs generated in ImmunoCult™-ACF Dendritic Cell Medium induced proliferation of allogeneic and antigen-specific T cells similar to DCs generated in either competitor media. Competitors 1 and 2, include in no particular order, CellGro DC Medium (CellGenix) and PromoCell DC Generation Medium DXF.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

文献 (2)

Development of an iPSC-derived immunocompetent skin model for identification of skin sensitizing substances M. Dubau et al. Journal of Tissue Engineering 2025 May

Abstract

The development of immunocompetent skin models marks a significant advancement in in vitro methods for detecting skin sensitizers while adhering to the 3R principles,which aim to reduce,refine,and replace animal testing. This study introduces for the first time an advanced immunocompetent skin model constructed entirely from induced pluripotent stem cell (iPSC)-derived cell types,including fibroblasts (iPSC-FB),keratinocytes (iPSC-KC),and fully integrated dendritic cells (iPSC-DC). To evaluate the skin model’s capacity,the model was treated topically with a range of well-characterized skin sensitizers varying in potency. The results indicate that the iPSC-derived immunocompetent skin model successfully replicates the physiological responses of human skin,offering a robust and reliable alternative to animal models for skin sensitization testing,allowing detection of extreme and even weak sensitizers. By addressing critical aspects of immune activation and cytokine signaling,this model provides an ethical,comprehensive tool for regulatory toxicology and dermatological research.

View publication

Engineering Human Donor Derived Germinal Center-Like Organoids (GCLOs) for Studying Immune Response to Vaccination. B. Suthar et al. Advanced science (Weinheim,Baden-Wurttemberg,Germany) 2026 Jul

Abstract

Germinal centers (GCs) are transient microanatomical structures that coordinate humoral immune responses through dynamic interactions between antigen presenting cells,T follicular helper cells,and B cells. Despite their central importance to immune protection,GC human biology remains difficult to interrogate due to significant inter-species variability,limited experimental accessibility to primary human tissues,and high interindividual variability. We developed a human immune culture platform that supports spontaneous multicellular organization of human peripheral blood mononuclear cells derived from primary CD19+ B cells,memory CD4+ T cells,and monocyte-derived dendritic cells into Germinal Center-like Organoids (GCLOs). These bioengineered GCLOs self-organize into stable clusters that exhibit stimulus and donor dependent differences in cellular composition and function. We observed the emergence of GC-like T and B cell subsets,functional IgG output,and the appearance of plasmablast-like populations. Notably,the age of the donors and the type of stimuli influenced GCLOs architecture,immune subsets,and antibody output. Platform outputs showed correspondence with clinical vaccine responsiveness across human donors,capturing inter-individual differences in humoral GCLO immune responses to the flu vaccine,including age-associated trends consistent with immunosenescence. This platform allows scalable investigation of human GC-associated immune features and provides a tractable framework for studying donor heterogeneity in humoral immunity.

View publication

View All Publications

更多信息

更多信息
物种	人
配方	不含动物成分, 无血清

ImmunoCult™-ACF树突状细胞分化添加物

产品号 #10988

产品号 #（选择产品）

产品号 #10988_C

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

ImmunoCult™-ACF树突状细胞分化添加物

产品号 #10988

产品号 #（选择产品）

产品号 #10988_C

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (7)

文献 (2)

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台